In the world, cardiac-related deaths are the first and cancer-related deaths are the third. Both cardiology and oncology developments, with an increase in early diagnosis and treatment possibilities, are accompanied by a decrease in mortality rate and a prolonged life span. Chemotherapeutic drugs and radiotherapies used to survive the life span of cancer patients have a toxic effect on the heart, and these patients also have to cope with cardiovascular problems.
At the end of the cardiotoxic effects of chemotherapeutic drugs,
Cardiac insufficiency and KMP (Cardiomyopathy) due to cardiac dysfunction,
Cardiac arrest and fluid collection,
Rhythm and communication disorders,
Coronary ischemia,
Hypertension or hypotension and thrombo-embolic events can be seen.
Radiotherapy is:
Contraction of coronary vessels,
Heart failure due to myocarditis,
Restrictive KMP,
Contraction or inability to cover,
Fibrosis-bound blocks in the transmission system,
Pericardial fibrosis can lead to diseases such as consequent constrictive pericarditis.
The on-cardial effects of the oncologic drugs used can be acute (during drug treatment) or chronic (early - up to 1 year, late - over 1 year). The cardiotoxic effects of oncologic drugs may be in the form of changes in the type of the drug and the amount of dose used, which usually do not improve (type 1) and are independent of the drug dose and improve after drug withdrawal (type 2).
Cardiotoxicity frequency due to oncologic drugs; (Age, gender, presence of cardiovascular risk factors, cardiovascular risk factors, and other factors related to the patient), the type of medication, the amount of dose given every cycle, the cumulative dose, treatment schedule, Whether or not the diseases are present.
Therefore, cardiologic evaluation should be performed at the intervals determined according to the condition of the patient before, during and after the treatment, and treatment should be started when the toxic effect is detected. The follow-up of cancer patients is now carried out by a multidisciplinary approach and is carried out by Cardio-Oncology teams, where cardiology and oncology specialists are involved.